FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

6 letters match. Newest first.

  1. Revlon Group Holdings, LLC

    FDA cited Revlon's Oxford, NC over-the-counter drug plant for failing to test talc for asbestos and weak quality oversight.

    High risk
  2. AQ USA Inc., d.b.a Ross Healthcare Inc.

    FDA warns AQ USA/Ross Healthcare over current good manufacturing practice violations in drugs, including missing microbial testing and inadequate component and stability controls.

    High risk
  3. Colgate-Palmolive/Tom's of Maine, Inc.

    FDA cited Tom's of Maine for CGMP failures after finding objectionable microbes in water and toothpaste and inadequate complaint handling.

    High risk
  4. Zermat International S.A. de C.V.

    FDA warns Zermat International about current good manufacturing practice violations for OTC drugs, including releasing out-of-specification lots without investigation.

    High risk
  5. Kobayashi Healthcare International, Inc.

    Kobayashi's Georgia plant released Zim's OTC pain drugs without microbial testing and lacked quality unit oversight, FDA says.

    High risk
  6. Dr Retter Ec Wladyslaw Retter

    FDA warns Dr Retter Ec Wladyslaw Retter over manufacturing failures for homeopathic drug cream.

    High risk